A certified solution standard suitable for use as starting material in calibrators or controls for a variety of LC/MS or GC/MS applications from forensic analysis and clinical toxicology to urine drug testing and pharmaceutical research. Bupropion is an antidepressant and smoking cessation drug sold under the trade names Wellbutrin® and Zyban®.
法律資訊
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Wellbutrin is a registered trademark of GlaxoSmithKline LLC
Zyban is a registered trademark of Everris International B.V.
Annals of internal medicine, 158(9), 667-675 (2013-05-08)
Tobacco use is responsible for a large proportion of the total disease burden from tuberculosis. Pakistan is one of the 10 high-burden countries for both tuberculosis and tobacco use. To assess the effectiveness of a behavioral support intervention and bupropion
The Cochrane database of systematic reviews, 2(2), CD007253-CD007253 (2013-03-02)
Individuals with schizophrenia smoke more heavily than the general population and this contributes to their higher morbidity and mortality from smoking-related illnesses. It remains unclear what interventions can help them to quit or to reduce smoking. To evaluate the benefits
European respiratory review : an official journal of the European Respiratory Society, 22(127), 37-43 (2013-03-05)
The mainstay in smoking cessation is counselling in combination with varenicline, nicotine replacement therapy (NRT) or bupropion SR. Varenicline and combination of two NRTs is equally effective, while varenicline alone is more effective than either NRT or bupropion SR. NRT
Mayo Clinic proceedings, 88(3), 226-233 (2013-03-16)
To compare the effectiveness of varenicline and combination nicotine replacement therapy (NRT) for treating smokers attempting to stop, as it is unclear which of the 2 is more effective. Data from 167,487 treatment episodes in patients from 42 National Health
The Journal of family practice, 62(2), 102-103 (2013-02-14)
Several treatments produce modest, but statistically significant, clinical increases in sexual desire and function in women. The testosterone transdermal patch improves hypoactive sexual desire disorder (HSDD) in postmenopausal women.